All In Biotech

Free tool

FAERS Monitor: Eylea

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125387 or its brand name (Eylea, Aflibercept). Reports on generic versions are filed under their own applications.

Reports

30,249

Serious

24,786

82% of reports

Hospitalization

3,966

Death reported

8,878

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death7,876
  • visual impairment2,037
  • off label use1,631
  • blindness1,437
  • endophthalmitis1,341
  • visual acuity reduced1,236
  • drug ineffective1,188
  • eye pain1,162
  • vision blurred1,149
  • product dose omission issue1,106
  • blindness unilateral1,048
  • blindness transient977
  • eye inflammation924
  • eye haemorrhage798
  • vitreous floaters780

Reports by year received

View as table
YearReports
20075
20082
200911
201045
201127
2012172
2013575
2014852
20151,499
20162,240
20172,841
20184,387
20194,417
20203,536
20211,917
20221,690
20231,473
20242,271
20251,098
20261,191

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,023,910 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
endophthalmitisSignal1,341199.8188.3205,962
blindness transientSignal977106.099.288,123
eye inflammationSignal92474.469.660,432
vitreous floatersSignal78059.955.741,523
blindness unilateralSignal1,04855.752.452,135
eye haemorrhageSignal79844.241.131,632
visual acuity reducedSignal1,23626.825.429,625
blindnessSignal1,43725.424.132,513
eye painSignal1,16214.613.814,444
visual impairmentSignal2,03711.611.119,519
deathSignal7,8766.46.337,118
vision blurredSignal1,1495.95.54,617
product dose omission issueSignal1,1062.62.51,119
off label use1,6311.31.2114
drug ineffective1,1880.60.6282

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.